Chinese medicine manufacturer initiates clinical heart trial in Singapore
Traditional Chinese medicine producer Tong Ren Tang announced clinical trials for its flagship cardiovascular formulation during a global medical conference hosted in Singapore
A Chinese medicine manufacturer announced plans to conduct an international clinical trial of its flagship heart remedy in Singapore. Wang Lei, chairman of Da Ren Tang and president of Tianjin Pharmaceutical Group, made the announcement at the 23rd World Congress of Chinese Medicine in Singapore. The study, a collaboration between Da Ren Tang and Singapore General Hospital, will be the first of its kind for a Chinese proprietary medicine conducted at a major Western-medicine hospital.
The company's CEO emphasized the holistic approach of Chinese medicine and its potential to strengthen public health systems in aging societies and regions grappling with chronic disease.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
